The Human Variable 

The COVID-19 pandemic has added another layer of immune instability through persistent inflammation, viral reactivations, and population-wide biologic stress . CRATE™ converts these complex dynamics into actionable modeling signals to inform future prevention strategy

The CYNAERA Primary Chronic Trigger (PCT) framework embeds PEM as a probability-weighted conversion event inside a prevalence model that accounts for viral exposure, environmental load, climate volatility, and recovery suppression. Modeled remission rises from historical 12–18 percent toward 35–50 percent under PEM-aware, terrain-timed designs, with early-intervention subsets reaching 42–60 percent in best-case conditions.

Bioadaptive Systems Therapeutics™ (BST) is a new discipline of medicine that engineers remission by recalibrating fragile biological systems across immune, autonomic, mitochondrial, connective, hormonal, and environmental domains. Unlike traditional medicine, which classifies disease onset and treats within rigid silos, BST is phase-aware, terrain-first, and subtype-specific.

Introduction Myalgic encephalomyelitis/chronic fatigue syndrome is common, costly, and routinely missed until someone reads the chart as a timeline. Patients describe a delayed crash after effort that lasts days to weeks. CDC and NICE name this pattern post-exertional malaise and make it central to diagnosis (CDC, 2024; NICE NG206, 2021). Yet most people with ME/CFS still do not have a diagnosis, and many wait years for recognition, with the National Academies reporting both

Innovative Orthostatic Intolerance & POTS Detection for Faster Diagnosis. Orthostatic intolerance and POTS are increasingly more common, disabling, and often missed until someone reads the chart as a timeline. The signs of these conditions already lives in routine positions and vitals clinicians collect anyway: triage after upright waiting, first supine on the bed, a short bathroom walk and return, and discharge.

Developed through over 40 failed trial reconstructions of 20+ conditions, SPARC™ decodes clinical heterogeneity using patient-derived intelligence and CYNAERA’s AI-integrated logic stacks. Each failed trial costs between $20–40 million, and in rare or stigmatized conditions, these failures permanently deter further investment. Most failed trials didn’t fail because the drug was weak. They failed because the patient groups were misread.